# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0...
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...